baclofen and MS (Multiple Sclerosis) studies

Research Excerpts

Excerpt	Relevance	Reference
"The aim of this study was to compare the relative efficacy of baclofen and self-applied transcutaneous electrical nerve stimulation (TENS) for the treatment of spasticity in the lower extremities in multiple sclerosis (MS)."	9.17	Comparison of the effect of baclofen and transcutaneous electrical nerve stimulation for the treatment of spasticity in multiple sclerosis. ( Golabchi, K; Haghighi, S; Heshmatipour, M; Janghorbani, M; Shaygannejad, V; Vaezi, A, 2013)
"We tested the hypothesis that changes in soleus stretch reflex was correlated to changes in intrathecal baclofen dose in 12 multiple sclerosis patients with moderate-severe spasticity treated with intrathecal baclofen pump."	9.11	Guided intrathecal baclofen administration by using soleus stretch reflex in moderate-severe spastic multiple sclerosis patients with implanted pump. ( Nielsen, JF; Sinkjaer, T, 2004)
"The effect of baclofen on the soleus stretch reflex and peripheral muscle function was tested in 10 multiple sclerosis (MS) patients with spasticity in the lower extremities."	9.09	Peripheral and central effect of baclofen on ankle joint stiffness in multiple sclerosis. ( Nielsen, JF; Sinkjaer, T, 2000)
"The effect of baclofen on walking performance was examined in nine spastic multiple sclerosis patients."	9.09	Baclofen increases the soleus stretch reflex threshold in the early swing phase during walking in spastic multiple sclerosis patients. ( Anderson, JB; Nielsen, JF; Sinkjaer, T, 2000)
"A multi-centre, double-blind study was carried out in 100 patients suffering from chronic spasticity due to multiple sclerosis to compare the effectiveness of tizanidine hydrochloride with that of baclofen."	9.06	Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. ( Boisson, D; Eyssette, M; Rohmer, F; Serratrice, G; Warter, JM, 1988)
"The anti-spastic effect of a new drug, tizanidine, was compared with that of baclofen in a double-blind clinical trial; 40 seriously handicapped patients with multiple sclerosis (MS) were randomly allocated treatment with one or the other drug for a 6-week period."	9.06	The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen. ( Nordal, HJ; Oftedal, SI; Slettebø, M; Stien, R, 1987)
"A double-blind trial with two parallel groups was carried out to compare the antispastic effect and tolerability of a new muscle relaxant, tizanidine (DS 103-282), with those of baclofen in the treatment of spasticity due to multiple sclerosis."	9.05	A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. ( Muff, S; Smolenski, C; Smolenski-Kautz, S, 1981)
"A double-blind, five-week, multicenter trial was conducted to compare the effect of baclofen, a unique amino acid derivative, with that of placebo in the treatment of 106 patients with spasticity secondary to multiple sclerosis."	9.04	Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis. ( Carey, MS; Logue, JN; Sachais, BA, 1977)
"Baclofen is a safe and effective means for treating spasticity associated with multiple sclerosis."	9.04	Baclofen for spasticity in multiple sclerosis. Double-blind crossover and three-year study. ( Conomy, JP; Feldman, RG; Foley, JM; Kelly-Hayes, M, 1978)
"Baclofen was used in a double-blind crossover placebo-controlled trial to treat spasticity in patients with multiple sclerosis (MS)."	9.04	The use of baclofen in treatment of spasticity in multiple sclerosis. ( Paty, DW; Sawa, GM, 1979)
"Two patients previously implanted with intrathecal Baclofen (ITB) pumps for management of intractable spasticity due to multiple sclerosis (MS) were referred to our center for ongoing management of their spasticity."	7.91	Intrathecal Baclofen Therapy in Patients With Multiple Sclerosis: Improved Outcomes and Reduced Costs Through Identification of Catheter Malfunction. ( McGuire, JR; Nelson, MES, 2019)
" In this study the authors analyzed the long term effects of intrathecal baclofen therapy in multiple sclerosis and evalued the benefits of the treatment on spasticity, disability, pain, spasm frequency and rated the incidence of side effects."	7.83	Long-term effects of intrathecal baclofen in multiple sclerosis. ( D'Oria, S; Gentile, M; Natale, M; Nero, VV; Rotondo, M; Squillante, E, 2016)
"Intrathecal Baclofen is available to treat severe generalized spasticity in Multiple Sclerosis (MS) unresponsive to oral drug delivery."	7.83	Effects of severe spasticity treatment with intrathecal Baclofen in multiple sclerosis patients: Long term follow-up. ( Gerini, A; Mazzoleni, S; Stampacchia, G, 2016)
"Tetrahydrocannabinol:cannabidiol (THC:CBD) oromucosal spray (Sativex®) is an add-on therapy for moderate-to-severe multiple sclerosis (MS)-related drug-resistant spasticity (MSS)."	7.83	Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice. ( Trojano, M; Vermersch, P, 2016)
"Our objective was to assess the role of Intrathecal Baclofen Therapy (ITB) in the cortical reorganization in a patient affected by multiple sclerosis (MS) undergoing physical therapy."	7.80	Cortical reorganization in multiple sclerosis after intrathecal baclofen therapy. ( Baglieri, A; Bramanti, P; Ciurleo, R; Corallo, F; De Luca, R; De Salvo, S; Guerrera, S; Marino, MA; Marino, S; Morabito, R; Spadaro, L; Timpano, F, 2014)
"To investigate the long-term dosage evolution and complication rate of intrathecal baclofen use in multiple sclerosis and spinal cord injury patients, based on a large population with a long follow-up."	7.79	Intrathecal baclofen in multiple sclerosis and spinal cord injury: complications and long-term dosage evolution. ( Degraeuwe, B; Draulans, N; Kiekens, C; Meurrens, T; Nuttin, B; Peers, K; Vermeersch, K, 2013)
"To evaluate the long-term effect of intrathecal baclofen therapy in multiple sclerosis-related spasticity and to evaluate the side-effects of long-term therapy, and the doses of baclofen required."	7.77	Treatment of spasticity related to multiple sclerosis with intrathecal baclofen: a long-term follow-up. ( Grønning, M; Rekand, T, 2011)
"A baclofen pump system was removed from a 47-year-old man with spasticity related to multiple sclerosis."	7.75	Cranial migration of a baclofen pump catheter associated with subarachnoid hemorrhage: case report. ( Bambakidis, NC; Consiglieri, GD; Garrett, MP; Nakaji, P; Shetter, AG, 2009)
"Intrathecal baclofen is a GABA-receptor agonist and one of the mainstay treatments of severe spasticity due to multiple sclerosis (MS)."	7.74	The safety of baclofen in pregnancy: intrathecal therapy in multiple sclerosis. ( Buckley, L; Dalton, CM; Jarrett, L; Keenan, E; Stevenson, VL, 2008)
"Oral and intrathecal baclofen (ITB) have been associated with epileptic seizures."	7.73	Incidence of seizures in patients with multiple sclerosis treated with intrathecal baclofen. ( Bethoux, FA; Boulis, N; Kellinghaus, C; Loddenkemper, T; Schuele, SU; Shook, SJ, 2005)
"We conducted a retrospective study of the case files of 64 multiple sclerosis (MS) patients presenting severe spasticity, who had received intrathecal (IT) baclofen test injections between 1992 and 2004 in a rehabilitation unit."	7.73	Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients. ( Ben Smail, D; Bussel, B; Mailhan, L; Peskine, A; Roche, N; Thiébaut, I, 2006)
"The authors present the case of a 49-year-old woman with disabling bilateral upper-extremity cerebellar tremor that resolved unexpectedly after placement of an intrathecal baclofen pump for lower-extremity spasticity."	7.72	Attenuation of cerebellar tremor with implantation of an intrathecal baclofen pump: the role of gamma-aminobutyric acidergic pathways. Case report. ( Lenz, FA; North, RB; Ohara, S; Weiss, N, 2003)
"To measure the effect of baclofen on the transmission in different spinal pathways to soleus motoneurones in spastic multiple sclerosis patients."	7.70	The effect of baclofen on the transmission in spinal pathways in spastic multiple sclerosis patients. ( Crone, C; Krarup, C; Nielsen, J; Orsnes, G; Petersen, N, 2000)
"We reviewed a 10% random sample of charts from an outpatient clinic for multiple sclerosis to determine the frequency with which baclofen was prescribed for spasticity in high doses (greater than 80 mg/d)."	7.68	High-dose oral baclofen: experience in patients with multiple sclerosis. ( Giesser, BS; LaRocca, NG; Scheinberg, LC; Smith, CR, 1991)
"Sixteen patients suffering from spasticity due to multiple sclerosis were treated with baclofen and tizanidine in a partially blind cross-over study."	7.67	Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients. ( Hoogstraten, MC; Minderhoud, JM; van der Ploeg, RJ; van Marle, S; vd Burg, W; Vreeling, A, 1988)
"Tizanidine (Sirdalud) was compared to baclofen (Lioresal) in a randomized, double-blind, cross-over trial."	6.66	Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. ( Bass, B; Bouchard, S; Cameron, MG; Ebers, GC; Hader, W; Noseworthy, JH; Rice, GP; Weinshenker, B, 1988)
"Oral antispasticity medications are useful in managing mild spasticity but are frequently ineffective in controlling moderate to severe spasticity, because patients often cannot tolerate the adverse effects of increasing doses."	6.47	Intrathecal baclofen in multiple sclerosis: too little, too late? ( Bennett, SE; Bethoux, F; Erwin, A; Gudesblatt, M; Hughes, M; Koelbel, S; Plunkett, R; Sadiq, S; Stevenson, VL; Thomas, AM; Tornatore, C; Zaffaroni, M, 2011)
"Usually, the evaluation of spasticity is carried out by the Asworth Scale although there is not yet general accordance on the validity of this scale."	6.44	Management of spasticity in multiple sclerosis by intrathecal baclofen. ( Dario, A; Tomei, G, 2007)
"Symptomatic treatment of Multiple Sclerosis (MS) is crucial, since it helps to lessen the limitations that affect patients' daily lives."	5.91	Effects of intrathecal Baclofen in reducing tremors in patients with multiple sclerosis. ( Aldarwish, WA; Ali, EN, 2023)
"Multiple sclerosis is a neurological disease that presents with various symptoms; in some cases it is progressive and highly disabling, requiring invasive techniques to treat pain and spasticity."	5.62	Intrathecal baclofen pump exchange in multiple sclerosis. Factors affecting baclofen efficacy and dose adjustement. A case report. ( Alonso Rodríguez, E; Blázquez Calvo, V; Lloreda Herradón, P; Miyagi Yonamine, M, 2021)
"The majority were on multiple spasticity medications."	5.62	Evaluation of the cognitive benefits of intrathecal baclofen pump implantation in people with intractable multiple sclerosis related spasticity. ( Buchanan, K; Doogan, C; Farrell, R; Keenan, E; Lee, H; Mulhert, N; Padilla, H; Stevenson, VL; Summers, M, 2021)
"Demographics, spasticity scores (Ashworth), spasm score (Penn), stiffness, pain and discomfort (Visual Analogue Scale), mobility (10 M walk), spasticity treatment, and ITB doses were analysed longitudinally."	5.51	Intrathecal baclofen for multiple sclerosis related spasticity: A twenty year experience. ( Buchanan, K; Farrell, R; Keenan, L; Sammaraiee, Y; Stevenson, V; Yardley, M, 2019)
"Melatonin is an effective treatment in MS patients and experimental autoimmune encephalomyelitis (EAE), a mouse model of MS."	5.48	Spasticity Treatment Ameliorates the Efficacy of Melatonin Therapy in Experimental Autoimmune Encephalomyelitis (EAE) Mouse Model of Multiple Sclerosis. ( Farhadi, N; Ghareghani, M; Sadeghi, H; Zibara, K, 2018)
"Successful treatment of severe spasticity represents an imperative of symptomatic therapy of multiple sclerosis (MS) due to a significant improvement of physical, psychic and social rehabilitation of MS patients, as well as a long-term cost savings for the additional treatments of conditions arising from uncontrolled severe spasticity."	5.33	[Treatment of severe spacticity in multiple sclerosis by continuous intrathecal baclofen]. ( Antić, B; Arsić, S; Dincić, E; Obradović, D; Perić, P, 2006)
"The aim of this study was to compare the relative efficacy of baclofen and self-applied transcutaneous electrical nerve stimulation (TENS) for the treatment of spasticity in the lower extremities in multiple sclerosis (MS)."	5.17	Comparison of the effect of baclofen and transcutaneous electrical nerve stimulation for the treatment of spasticity in multiple sclerosis. ( Golabchi, K; Haghighi, S; Heshmatipour, M; Janghorbani, M; Shaygannejad, V; Vaezi, A, 2013)
"We tested the hypothesis that changes in soleus stretch reflex was correlated to changes in intrathecal baclofen dose in 12 multiple sclerosis patients with moderate-severe spasticity treated with intrathecal baclofen pump."	5.11	Guided intrathecal baclofen administration by using soleus stretch reflex in moderate-severe spastic multiple sclerosis patients with implanted pump. ( Nielsen, JF; Sinkjaer, T, 2004)
"The effect of baclofen on the soleus stretch reflex and peripheral muscle function was tested in 10 multiple sclerosis (MS) patients with spasticity in the lower extremities."	5.09	Peripheral and central effect of baclofen on ankle joint stiffness in multiple sclerosis. ( Nielsen, JF; Sinkjaer, T, 2000)
"The effect of baclofen on walking performance was examined in nine spastic multiple sclerosis patients."	5.09	Baclofen increases the soleus stretch reflex threshold in the early swing phase during walking in spastic multiple sclerosis patients. ( Anderson, JB; Nielsen, JF; Sinkjaer, T, 2000)
"A convenience sample of nine consecutively recruited men with spinal cord injury or multiple sclerosis who were receiving intrathecal baclofen by an implantable pump; average follow-up was 44."	5.08	Side effects of chronic intrathecal baclofen on erection and ejaculation in patients with spinal cord lesions. ( Azouvi, P; Bussel, B; Chartier-Kastler, E; Denys, P; Mane, M; Thiebaut, JB, 1998)
"This study assessed the safety and efficacy of intrathecal baclofen in the treatment of intractable spasticity caused by spinal cord injury or multiple sclerosis."	5.07	Intrathecal baclofen for treatment of intractable spinal spasticity. ( Abel, NA; Smith, RA, 1994)
"A total of 93 patients with intractable spasticity due to either spinal cord injury (59 cases), multiple sclerosis (31 cases), or other spinal pathology (three cases) were entered into a randomized double-blind placebo-controlled screening protocol of intrathecal baclofen test injections."	5.07	Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. ( Cahill, D; Coffey, JR; Gill, B; Herman, R; Levy, R; Meythaler, J; Ordia, J; Park, TS; Shetter, AG; Steers, W, 1993)
"In a double-blind comparative study, the therapeutic efficacy and safety of three centrally effective antispasmodics (Tetrazepam, Baclofen and Tizanidine) in patients suffering from multiple sclerosis with spastic motor disturbances of the lower extremities was to be examined."	5.06	[Comparative double-blind study of the effectiveness and tolerance of baclofen, tetrazepam and tizanidine in spastic movement disorders of the lower extremities]. ( Paulig, M; Pellkofer, M, 1989)
"A multi-centre, double-blind study was carried out in 100 patients suffering from chronic spasticity due to multiple sclerosis to compare the effectiveness of tizanidine hydrochloride with that of baclofen."	5.06	Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. ( Boisson, D; Eyssette, M; Rohmer, F; Serratrice, G; Warter, JM, 1988)
"The anti-spastic effect of a new drug, tizanidine, was compared with that of baclofen in a double-blind clinical trial; 40 seriously handicapped patients with multiple sclerosis (MS) were randomly allocated treatment with one or the other drug for a 6-week period."	5.06	The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen. ( Nordal, HJ; Oftedal, SI; Slettebø, M; Stien, R, 1987)
"A double-blind trial with two parallel groups was carried out to compare the antispastic effect and tolerability of a new muscle relaxant, tizanidine (DS 103-282), with those of baclofen in the treatment of spasticity due to multiple sclerosis."	5.05	A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. ( Muff, S; Smolenski, C; Smolenski-Kautz, S, 1981)
"A double-blind, five-week, multicenter trial was conducted to compare the effect of baclofen, a unique amino acid derivative, with that of placebo in the treatment of 106 patients with spasticity secondary to multiple sclerosis."	5.04	Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis. ( Carey, MS; Logue, JN; Sachais, BA, 1977)
"25 patients with multiple sclerosis (MS) and other spastic disorders, 33 MS patients and 10 control patients with MS were given clonazepam, baclofen or placebo over a period of 5 days to 20 weeks."	5.04	Clonazepam, baclofen and placebo in the treatment of spasticity. ( Cendrowski, W; Sobczyk, W, 1977)
"Baclofen is a safe and effective means for treating spasticity associated with multiple sclerosis."	5.04	Baclofen for spasticity in multiple sclerosis. Double-blind crossover and three-year study. ( Conomy, JP; Feldman, RG; Foley, JM; Kelly-Hayes, M, 1978)
"Baclofen was used in a double-blind crossover placebo-controlled trial to treat spasticity in patients with multiple sclerosis (MS)."	5.04	The use of baclofen in treatment of spasticity in multiple sclerosis. ( Paty, DW; Sawa, GM, 1979)
"Baclofen is used for treatment of the spasticity of spinal origin that is a common sequela of spinal cord injury and multiple sclerosis; spasticity occurs in about 50% of patients affected by these disorders."	4.82	A benefit-risk assessment of baclofen in severe spinal spasticity. ( Dario, A; Tomei, G, 2004)
"Two patients previously implanted with intrathecal Baclofen (ITB) pumps for management of intractable spasticity due to multiple sclerosis (MS) were referred to our center for ongoing management of their spasticity."	3.91	Intrathecal Baclofen Therapy in Patients With Multiple Sclerosis: Improved Outcomes and Reduced Costs Through Identification of Catheter Malfunction. ( McGuire, JR; Nelson, MES, 2019)
" In this study the authors analyzed the long term effects of intrathecal baclofen therapy in multiple sclerosis and evalued the benefits of the treatment on spasticity, disability, pain, spasm frequency and rated the incidence of side effects."	3.83	Long-term effects of intrathecal baclofen in multiple sclerosis. ( D'Oria, S; Gentile, M; Natale, M; Nero, VV; Rotondo, M; Squillante, E, 2016)
"Intrathecal Baclofen is available to treat severe generalized spasticity in Multiple Sclerosis (MS) unresponsive to oral drug delivery."	3.83	Effects of severe spasticity treatment with intrathecal Baclofen in multiple sclerosis patients: Long term follow-up. ( Gerini, A; Mazzoleni, S; Stampacchia, G, 2016)
"Tetrahydrocannabinol:cannabidiol (THC:CBD) oromucosal spray (Sativex®) is an add-on therapy for moderate-to-severe multiple sclerosis (MS)-related drug-resistant spasticity (MSS)."	3.83	Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice. ( Trojano, M; Vermersch, P, 2016)
"Our objective was to assess the role of Intrathecal Baclofen Therapy (ITB) in the cortical reorganization in a patient affected by multiple sclerosis (MS) undergoing physical therapy."	3.80	Cortical reorganization in multiple sclerosis after intrathecal baclofen therapy. ( Baglieri, A; Bramanti, P; Ciurleo, R; Corallo, F; De Luca, R; De Salvo, S; Guerrera, S; Marino, MA; Marino, S; Morabito, R; Spadaro, L; Timpano, F, 2014)
"To investigate the long-term dosage evolution and complication rate of intrathecal baclofen use in multiple sclerosis and spinal cord injury patients, based on a large population with a long follow-up."	3.79	Intrathecal baclofen in multiple sclerosis and spinal cord injury: complications and long-term dosage evolution. ( Degraeuwe, B; Draulans, N; Kiekens, C; Meurrens, T; Nuttin, B; Peers, K; Vermeersch, K, 2013)
"To evaluate the long-term effect of intrathecal baclofen therapy in multiple sclerosis-related spasticity and to evaluate the side-effects of long-term therapy, and the doses of baclofen required."	3.77	Treatment of spasticity related to multiple sclerosis with intrathecal baclofen: a long-term follow-up. ( Grønning, M; Rekand, T, 2011)
"A 44-year-old white woman with primary progressive MS receiving a multidrug of PO baclofen 75 mg/d, PO piracetam 3 g/d, and IV mitoxantrone 10 mg administered once a month presented to the Multiple Sclerosis Center, University of Catania, Catania, Italy."	3.75	Drug rash with eosinophilia and systemic signs syndrome in a patient with multiple sclerosis. ( Caruso, A; Neri, S; Patti, F; Vecchio, R, 2009)
"A baclofen pump system was removed from a 47-year-old man with spasticity related to multiple sclerosis."	3.75	Cranial migration of a baclofen pump catheter associated with subarachnoid hemorrhage: case report. ( Bambakidis, NC; Consiglieri, GD; Garrett, MP; Nakaji, P; Shetter, AG, 2009)
"A 52-year-old woman with bilateral leg spasticity because of spinal multiple sclerosis underwent baclofen pump implantation, which was subcutaneously placed in the right upper quadrant."	3.75	Tangled catheter as a rare cause of baclofen pump malfunction. ( Fukuhara, T; Kuyama, H; Namba, Y; Tanaka, T, 2009)
"Intrathecal baclofen is a GABA-receptor agonist and one of the mainstay treatments of severe spasticity due to multiple sclerosis (MS)."	3.74	The safety of baclofen in pregnancy: intrathecal therapy in multiple sclerosis. ( Buckley, L; Dalton, CM; Jarrett, L; Keenan, E; Stevenson, VL, 2008)
"Oral and intrathecal baclofen (ITB) have been associated with epileptic seizures."	3.73	Incidence of seizures in patients with multiple sclerosis treated with intrathecal baclofen. ( Bethoux, FA; Boulis, N; Kellinghaus, C; Loddenkemper, T; Schuele, SU; Shook, SJ, 2005)
"We conducted a retrospective study of the case files of 64 multiple sclerosis (MS) patients presenting severe spasticity, who had received intrathecal (IT) baclofen test injections between 1992 and 2004 in a rehabilitation unit."	3.73	Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients. ( Ben Smail, D; Bussel, B; Mailhan, L; Peskine, A; Roche, N; Thiébaut, I, 2006)
"The authors present the case of a 49-year-old woman with disabling bilateral upper-extremity cerebellar tremor that resolved unexpectedly after placement of an intrathecal baclofen pump for lower-extremity spasticity."	3.72	Attenuation of cerebellar tremor with implantation of an intrathecal baclofen pump: the role of gamma-aminobutyric acidergic pathways. Case report. ( Lenz, FA; North, RB; Ohara, S; Weiss, N, 2003)
"The objective of this study was to characterize the population of multiple sclerosis (MS) patients suffering from spasticity and to evaluate treatment patterns, including intrathecal baclofen (ITB) delivery, related to patient quality of life (QOL)."	3.72	Prevalence and treatment of spasticity reported by multiple sclerosis patients. ( Hadjimichael, OC; Preiningerova, J; Rizzo, MA; Vollmer, TL, 2004)
"To measure the effect of baclofen on the transmission in different spinal pathways to soleus motoneurones in spastic multiple sclerosis patients."	3.70	The effect of baclofen on the transmission in spinal pathways in spastic multiple sclerosis patients. ( Crone, C; Krarup, C; Nielsen, J; Orsnes, G; Petersen, N, 2000)
"A total of 66 consecutive patients with severe spasticity of spinal cord origin were screened with intrathecal baclofen, and all but two responded with a two-point decrease in their Ashworth spasticity scale and/or spasm scale score."	3.68	Intrathecal baclofen for spasticity of spinal origin: seven years of experience. ( Penn, RD, 1992)
"We reviewed a 10% random sample of charts from an outpatient clinic for multiple sclerosis to determine the frequency with which baclofen was prescribed for spasticity in high doses (greater than 80 mg/d)."	3.68	High-dose oral baclofen: experience in patients with multiple sclerosis. ( Giesser, BS; LaRocca, NG; Scheinberg, LC; Smith, CR, 1991)
"Sixteen patients suffering from spasticity due to multiple sclerosis were treated with baclofen and tizanidine in a partially blind cross-over study."	3.67	Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients. ( Hoogstraten, MC; Minderhoud, JM; van der Ploeg, RJ; van Marle, S; vd Burg, W; Vreeling, A, 1988)
"The efficacy of intrathecally administered baclofen was demonstrated in three patients with different types of muscular hypertonia (supraspinal rigidity, spasms shortly after spinal trauma, spasms for many years induced by multiple sclerosis) using integrated electromyography."	3.67	The effect of intrathecal baclofen on electrical muscle activity in spasticity. ( Börner, U; Dralle, D; Hoffmann, O; Müller, H; Zierski, J, 1987)
"The intrathecal administration of baclofen by way of an implanted subcutaneous drug delivery system is described in a patient with a severe spastic paraparesis due to multiple sclerosis."	3.67	Intrathecal baclofen for severe spasticity. ( Hankey, GJ; Perlman, D; Stewart-Wynne, EG, 1986)
"We aimed to determine whether antispasticity treatment history influenced the efficacy and safety of add-on THC:CBD oromucosal spray in MS spasticity patients."	2.82	Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity. ( Álvarez-Ossorio, L; Haupts, M; Jonas, A; Vila, C; Witte, K, 2016)
"When a sleep apnea syndrome was preexisting, it was generally severely worsened by the bolus mode of administration."	2.77	Pilot study assessing the impact of intrathecal baclofen administration mode on sleep-related respiratory parameters. ( Bensmail, D; Godard, AL; Lofaso, F; Marquer, A; Quera-Salva, MA; Roche, N, 2012)
"Fourteen spastic MS patients were examined in a placebo controlled double-blind, cross-over trial of oral baclofen treatment."	2.69	Effect of baclofen on gait in spastic MS patients. ( Larsen, TK; Orsnes, GB; Ravnborg, M; Sørensen, PS, 2000)
"Severe spasticity unresponsive to oral drugs may respond satisfactorily to baclofen delivered intrathecally."	2.68	Long-term intrathecal baclofen therapy in patients with intractable spasticity. ( Ablett, DP; Becker, WJ; DeForge, DA; Harris, CJ; Klein, GM; Long, ML, 1995)
" A reduction in dosage was necessitated by muscular hypotonia in three ambulatory patients, areflexic bladder and urinary retention in three others, and nausea, dizziness, and drowsiness in one."	2.68	Chronic intrathecal delivery of baclofen by a programmable pump for the treatment of severe spasticity. ( Adamski, E; Fischer, E; Ordia, JI; Spatz, EL, 1996)
"Patients with minimal to moderate spasticity were randomized to one of three sequences to evaluate the effects on MS-related spasticity of baclofen alone, stretching regimen with placebo, placebo alone, and stretching regimen with baclofen."	2.67	Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis. ( Brar, SP; Cobble, ND; Franklin, GM; Nelson, LM; Smith, MB, 1991)
"This procedure is recommended for spasticity of spinal origin refractory to physiotherapy and oral medication."	2.66	Intrathecal baclofen for long-term treatment of spasticity: a multi-centre study. ( Gardner, BP; Gybels, J; Jamous, A; Linderoth, B; Meyerson, BA; Ochs, G; Struppler, A; Teddy, P; Weinmann, P, 1989)
"Twenty patients with spinal spasticity caused by multiple sclerosis or spinal-cord injury who had had no response to treatment with oral baclofen received an intrathecal infusion of baclofen or saline for three days."	2.66	Intrathecal baclofen for severe spinal spasticity. ( Corcos, D; Gottlieb, G; Kroin, JS; Latash, M; Parke, B; Penn, RD; Savoy, SM, 1989)
"Tizanidine (Sirdalud) was compared to baclofen (Lioresal) in a randomized, double-blind, cross-over trial."	2.66	Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. ( Bass, B; Bouchard, S; Cameron, MG; Ebers, GC; Hader, W; Noseworthy, JH; Rice, GP; Weinshenker, B, 1988)
" Percentages of improved patients' spasticity scale, mild adverse effect and severe adverse effect were extracted as outcomes."	2.58	A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiple sclerosis: a systematic review and network meta-analysis. ( Fu, X; Li, J; Li, M; Ma, Q; Wang, C; Wang, Y; Wu, H; Yang, W, 2018)
"Treatment of spasticity poses a major challenge given the complex clinical presentation and variable efficacy and safety profiles of available drugs."	2.53	Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. ( Comi, G; Gold, R; Hartung, HP; Montalban, X; Otero-Romero, S; Sastre-Garriga, J; Soelberg Sørensen, P; Thompson, AJ; Vermersch, P, 2016)
"Of all drug use to treat MS symptoms, treatment for pain accounts for nearly 30 % of total use."	2.49	Pain and multiple sclerosis: pathophysiology and treatment. ( Messmer Uccelli, M; Solaro, C; Trabucco, E, 2013)
"The medicinal treatment of spasticity includes use of oral treatments (baclofène and tizanidine), botulinum toxin, intrathecal baclofène and local application of alcohol or phenol."	2.48	[Pharmacological treatment of spasticity in multiple sclerosis]. ( Heinzlef, O; Monteil-Roch, I, 2012)
"Oral antispasticity medications are useful in managing mild spasticity but are frequently ineffective in controlling moderate to severe spasticity, because patients often cannot tolerate the adverse effects of increasing doses."	2.47	Intrathecal baclofen in multiple sclerosis: too little, too late? ( Bennett, SE; Bethoux, F; Erwin, A; Gudesblatt, M; Hughes, M; Koelbel, S; Plunkett, R; Sadiq, S; Stevenson, VL; Thomas, AM; Tornatore, C; Zaffaroni, M, 2011)
"Disabling tremor or ataxia is common in multiple sclerosis (MS) and up to 80% of patients experience tremor or ataxia at some point during their disease."	2.44	Treatment for ataxia in multiple sclerosis. ( Mills, RJ; Yap, L; Young, CA, 2007)
"Usually, the evaluation of spasticity is carried out by the Asworth Scale although there is not yet general accordance on the validity of this scale."	2.44	Management of spasticity in multiple sclerosis by intrathecal baclofen. ( Dario, A; Tomei, G, 2007)
"Among the more common symptoms is spasticity."	2.41	Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis. ( Schapiro, RT, 2001)
"With the introduction of the antispasticity agent, tizanidine hydrochloride (Zanaflex), physicians have requested information about the optimal way to switch appropriate patients from baclofen to tizanidine."	2.40	An approach to switching patients from baclofen to tizanidine. ( Brenner, R; Hyman, N; Knobler, R; O'Brien, M; Stephan, T, 1998)
"Multiple sclerosis is a demyelinating disorder of the central nervous system characterized by exacerbations and remissions of symptoms."	2.38	Update on multiple sclerosis therapy. ( Mitchell, G, 1993)
"Baclofen is the treatment of choice for spasticity and is usually given in doses of 30 to 80 mg/day, although higher doses may be used."	2.37	Multiple sclerosis. Current concepts in management. ( Giesser, B, 1985)
"We aim to describe associations with spasticity treatment measured primarily by oral baclofen use."	1.91	Spasticity treatment patterns among people with multiple sclerosis: a Swedish cohort study. ( Alfredsson, L; Hillert, J; Kockum, I; Montgomery, S; Olsson, T; Piehl, F; Smith, KA; Stridh, P, 2023)
"Symptomatic treatment of Multiple Sclerosis (MS) is crucial, since it helps to lessen the limitations that affect patients' daily lives."	1.91	Effects of intrathecal Baclofen in reducing tremors in patients with multiple sclerosis. ( Aldarwish, WA; Ali, EN, 2023)
"Multiple sclerosis is a neurological disease that presents with various symptoms; in some cases it is progressive and highly disabling, requiring invasive techniques to treat pain and spasticity."	1.62	Intrathecal baclofen pump exchange in multiple sclerosis. Factors affecting baclofen efficacy and dose adjustement. A case report. ( Alonso Rodríguez, E; Blázquez Calvo, V; Lloreda Herradón, P; Miyagi Yonamine, M, 2021)
"The majority were on multiple spasticity medications."	1.62	Evaluation of the cognitive benefits of intrathecal baclofen pump implantation in people with intractable multiple sclerosis related spasticity. ( Buchanan, K; Doogan, C; Farrell, R; Keenan, E; Lee, H; Mulhert, N; Padilla, H; Stevenson, VL; Summers, M, 2021)
"Treatment of spasticity includes oral and intrathecal anti-spastic drugs, muscle injections with relaxant agents, physical therapy, electrical and magnetic stimulation and peripheral nerve stimulation, alone or in various combinations."	1.56	Italian consensus on treatment of spasticity in multiple sclerosis. ( Centonze, D; Comi, G; Leocani, L; Otero-Romero, S; Solari, A, 2020)
"Demographics, spasticity scores (Ashworth), spasm score (Penn), stiffness, pain and discomfort (Visual Analogue Scale), mobility (10 M walk), spasticity treatment, and ITB doses were analysed longitudinally."	1.51	Intrathecal baclofen for multiple sclerosis related spasticity: A twenty year experience. ( Buchanan, K; Farrell, R; Keenan, L; Sammaraiee, Y; Stevenson, V; Yardley, M, 2019)
"Melatonin is an effective treatment in MS patients and experimental autoimmune encephalomyelitis (EAE), a mouse model of MS."	1.48	Spasticity Treatment Ameliorates the Efficacy of Melatonin Therapy in Experimental Autoimmune Encephalomyelitis (EAE) Mouse Model of Multiple Sclerosis. ( Farhadi, N; Ghareghani, M; Sadeghi, H; Zibara, K, 2018)
"To examine dosing patterns in patients receiving baclofen via intrathecal baclofen pumps to assess for common patterns by diagnosis, ambulation ability, and affected limbs distribution."	1.43	Intrathecal Baclofen Dosing Regimens: A Retrospective Chart Review. ( Clearfield, JS; McGuire, J; Nelson, ME; Rein, LE; Tarima, S, 2016)
"Cross-sectional data on spasticity severity (using a Numerical Rating Scale, NRS), resource use and HRQoL (using EQ-5D) were collected using a patient questionnaire and chart review."	1.40	Costs and quality of life in multiple sclerosis patients with spasticity. ( Borg, S; Nilsson, P; Svensson, J, 2014)
"To assess the frequency and types of adverse events (AEs) related to intrathecal baclofen (ITB) therapy in adults, and associated risk factors."	1.40	Occurrence of adverse events in long-term intrathecal baclofen infusion: a 1-year follow-up study of 158 adults. ( Bensmail, D; Borrini, L; Hugeron, C; Jourdan, C; Rech, C; Thiebaut, JB, 2014)
"Acquired pendular nystagmus (APN) occurs with multiple sclerosis (MS) and oculopalatal tremor (OPT); distinct features of the nystagmus have led to the development of separate models for their pathogenesis."	1.37	Pharmacological tests of hypotheses for acquired pendular nystagmus. ( Leigh, RJ; Optican, LM; Shaikh, AG; Thurtell, MJ, 2011)
"Reduction of spasticity and spasms achieved with intrathecally delivered baclofen, leads to functional improvement and pain relief."	1.33	Functional outcome of intrathecal baclofen administration for severe spasticity. ( Boviatsis, EJ; Korfias, S; Kouyialis, AT; Sakas, DE, 2005)
"Successful treatment of severe spasticity represents an imperative of symptomatic therapy of multiple sclerosis (MS) due to a significant improvement of physical, psychic and social rehabilitation of MS patients, as well as a long-term cost savings for the additional treatments of conditions arising from uncontrolled severe spasticity."	1.33	[Treatment of severe spacticity in multiple sclerosis by continuous intrathecal baclofen]. ( Antić, B; Arsić, S; Dincić, E; Obradović, D; Perić, P, 2006)
"We assessed spasticity and obtained polysomnography, pulmonary function tests, and resting energy expenditure measurements 1 week before and at least 8 days after pump implantation."	1.33	Effect of intrathecal baclofen on sleep and respiratory function in patients with spasticity. ( Bensmail, D; Benyahia, S; Bohic, M; Bussel, B; Denys, P; Lofaso, F; Quera Salva, MA; Roche, N, 2006)
"Individuals with spasticity were found to have significantly higher levels of disability than those who had no spasticity or clinically insignificant spasticity."	1.32	Spasticity in multiple sclerosis. ( Barnes, MP; Kent, RM; McMullen, KM; Semlyen, JK, 2003)
"Severe hamstring spasticity was encountered in both patients in the immediate post-operative period requiring further surgery."	1.32	Total knee replacement in patients with multiple sclerosis. ( Cogley, D; Glynn, M; Shannon, FJ, 2004)
" The average dosage for the total group was 463 micrograms per day (microg/day), and 32% used a simple infusion mode."	1.32	Intrathecal baclofen therapy over 10 years. ( Rawlins, PK, 2004)
"Acquired Pendular Nystagmus (APN) may cause distressing visual symptoms in patients who are already suffering a severe general disease."	1.31	Improvement of acquired pendular nystagmus by gabapentin: case report. ( Fabre, K; Smet-Dieleman, H; Zeyen, T, 2001)
"Severe, uncontrolled spasticity resulting from spinal cord injury (SCI) and multiple sclerosis (MS) can have a profound effect on the patient's ability to function and thus, their quality of life."	1.30	Quality of life: effect of reduced spasticity from intrathecal baclofen. ( Gianino, JM; Paice, JA; Shott, S; York, MM, 1998)
"35 patients with severe spasticity, 29 of spinal origin and six of supraspinal origin resistant to conservative treatment, had a programmable pump (Synchromed, Medtronic) for continuous intrathecal baclofen infusion implanted."	1.30	[Continuous intrathecal infusion of baclofen. A new therapeutic method for spasticity]. ( Berg-Johnsen, J; Lundar, T; Røste, GK; Solgaard, T, 1998)
"Intrathecal baclofen abolishes spasticity in many patients with neurological diseases but there are few studies on its long-term effectiveness."	1.29	Management of severe spasticity with intrathecal baclofen delivered by a manually operated pump. ( Byrnes, D; Crowe, D; Lee, A; Patterson, V; Watt, M, 1994)
"Baclofen is a centrally acting muscle relaxant used for treatment of spasticity."	1.28	Clinical and pharmacokinetic aspects of high dose oral baclofen therapy. ( Aisen, ML; Cedarbaum, JM; Dietz, MA; Kutt, H; Rossi, P, 1992)
" The 18 patients selected for chronic administration were implanted with a programmable pump."	1.28	Chronic intrathecal baclofen administration for control of severe spasticity. ( Bastide, R; Carillo, JP; Lazorthes, Y; Sallerin-Caute, B; Verdie, JC, 1990)
"Six patients with long-lasting spasticity resistant to different drug therapies including oral baclofen received a bolus injection of lumbar intrathecal baclofen."	1.28	Short-term effects of intrathecal baclofen in spasticity. ( Corcos, DM; Gottlieb, GL; Latash, ML; Penn, RD, 1989)
"We report on a group of patients with spasticity not relieved by these methods."	1.28	Functional outcome after delivery of intrathecal baclofen. ( Corcos, D; Parke, B; Penn, RD; Savoy, SM, 1989)
"Twelve spastic patients received single oral doses of a new anti-spastic drug DS103-282 (Sandoz) 6 mg, baclofen 20 mg, and placebo on three separate days."	1.26	Double-blind comparison of single doses of DS103-282, baclofen and placebo for suppression of spasticity. ( Hassan, N; McLellan, DL, 1980)

Research

Studies (151)

Authors

Clinical Trials (8)

Trial Overview

Trial Outcomes

Subjects Experiencing Maximal MAS Change From Baseline - Spasticity of Cerebral Origin

Timeframe	Studies, this research(%)	All Research%
pre-1990	41 (27.15)	18.7374
1990's	28 (18.54)	18.2507
2000's	35 (23.18)	29.6817
2010's	38 (25.17)	24.3611
2020's	9 (5.96)	2.80

Authors	Studies
Serrano-Regal, MP	1
Bayón-Cordero, L	1
Chara Ventura, JC	1
Ochoa-Bueno, BI	1
Tepavcevic, V	1
Matute, C	1
Sánchez-Gómez, MV	1
Cinone, N	1
Santoro, L	1
Spina, S	1
Facciorusso, S	1
Battaglia, M	1
Baricich, A	1
Marcogiuseppe, P	1
Santamato, A	1
Smith, KA	1
Piehl, F	1
Olsson, T	1
Alfredsson, L	1
Hillert, J	1
Kockum, I	1
Stridh, P	1
Montgomery, S	1
Aldarwish, WA	1
Ali, EN	1
Comi, G	2
Solari, A	1
Leocani, L	1
Centonze, D	1
Otero-Romero, S	2
Lloreda Herradón, P	1
Blázquez Calvo, V	1
Miyagi Yonamine, M	1
Alonso Rodríguez, E	1
Sammaraiee, Y	2
Stevenson, VL	5
Keenan, E	3
Buchanan, K	3
Lee, H	2
Padilla, H	2
Farrell, RA	1
Jones, É	1
Vlachou, S	1
Farrell, R	2
Summers, M	1
Doogan, C	1
Mulhert, N	1
Behm, K	1
Morgan, P	1
Lee, BS	1
Jones, J	1
Lang, M	1
Achey, R	1
Dai, L	1
Lobel, DA	1
Nagel, SJ	1
Machado, AG	1
Bethoux, F	2
Devine, OP	1
Harborne, AC	1
Lo, WB	1
Price, R	1
Ghareghani, M	1
Zibara, K	1
Sadeghi, H	1
Farhadi, N	1
Fu, X	1
Wang, Y	1
Wang, C	1
Wu, H	1
Li, J	1
Li, M	1
Ma, Q	1
Yang, W	1
Arroyo González, R	1
Yardley, M	1
Keenan, L	1
Stevenson, V	1
Nelson, MES	1
McGuire, JR	1
Guerrera, S	1
Morabito, R	1
Baglieri, A	1
Corallo, F	1
Ciurleo, R	1
De Luca, R	1
De Salvo, S	1
Marino, MA	1
Spadaro, L	1
Timpano, F	1
Bramanti, P	2
Marino, S	1
Shaygannejad, V	1
Janghorbani, M	1
Vaezi, A	1
Haghighi, S	1
Golabchi, K	1
Heshmatipour, M	1
Svensson, J	1
Borg, S	1
Nilsson, P	1
Draulans, N	1
Vermeersch, K	1
Degraeuwe, B	1
Meurrens, T	1
Peers, K	1
Nuttin, B	1
Kiekens, C	1
Janus, TJ	1
Abrous-Anane, S	1
Benhassine, S	1
Lopez, S	1
Cristina, K	1
Mazeron, JJ	1
Borrini, L	1
Bensmail, D	3
Thiebaut, JB	3
Hugeron, C	1
Rech, C	1
Jourdan, C	1
Gunnarsson, S	1
Samuelsson, K	1
Rush, R	1
Kumbhare, D	1
Clearfield, JS	1
Nelson, ME	1
McGuire, J	1
Rein, LE	1
Tarima, S	1
Trojano, M	2
Natale, M	1
D'Oria, S	1
Nero, VV	1
Squillante, E	1
Gentile, M	1
Rotondo, M	1
Stampacchia, G	1
Gerini, A	1
Mazzoleni, S	1
Haupts, M	1
Vila, C	1
Jonas, A	1
Witte, K	1
Álvarez-Ossorio, L	1
Sastre-Garriga, J	1
Hartung, HP	1
Soelberg Sørensen, P	1
Thompson, AJ	1
Vermersch, P	2
Gold, R	1
Montalban, X	1
Vanopdenbosch, LJ	1
Oliver, DJ	1
Kass, JS	1
Dalton, CM	1
Jarrett, L	1
Buckley, L	1
Heetla, HW	2
Staal, MJ	2
Kliphuis, C	1
van Laar, T	2
Caruso, A	1
Vecchio, R	1
Patti, F	1
Neri, S	1
Nakaji, P	1
Consiglieri, GD	1
Garrett, MP	1
Bambakidis, NC	1
Shetter, AG	2
Khan, AA	1
Birks-Agnew, I	1
Bullock, P	1
Rushton, D	1
Erwin, A	1
Gudesblatt, M	1
Bennett, SE	1
Koelbel, S	1
Plunkett, R	1
Sadiq, S	1
Thomas, AM	1
Tornatore, C	1
Zaffaroni, M	1
Hughes, M	2
Rekand, T	1
Grønning, M	1
Shaikh, AG	1
Thurtell, MJ	1
Optican, LM	1
Leigh, RJ	1
Marquer, A	1
Roche, N	3
Godard, AL	1
Lofaso, F	2
Quera-Salva, MA	1
Bassani, L	1
Harter, DH	1
Berger, B	1
Vienenkoetter, B	1
Korporal, M	1
Rocco, A	1
Meinck, HM	1
Steiner, T	1
Heinzlef, O	1
Monteil-Roch, I	1
Stetkarova, I	1
Kofler, M	2
Russell, LJ	1
leRoux, AA	1
Wheelock, WB	1
Solaro, C	1
Trabucco, E	1
Messmer Uccelli, M	1
Fabre, K	1
Smet-Dieleman, H	1
Zeyen, T	1
Barnes, MP	1
Kent, RM	1
Semlyen, JK	1
McMullen, KM	1
Weiss, N	1
North, RB	1
Ohara, S	1
Lenz, FA	1
Dario, A	2
Tomei, G	2
Nielsen, JF	4
Sinkjaer, T	3
Rizzo, MA	1
Hadjimichael, OC	1
Preiningerova, J	1
Vollmer, TL	1
Zahavi, A	1
Geertzen, JH	1
Middel, B	1
Staal, M	1
Rietman, JS	1
Sarrigiannis, P	1
Tsakanicas, C	1
Anagnostouli, M	1
Karandreas, N	1
Shannon, FJ	1
Cogley, D	1
Glynn, M	1
Rawlins, PK	1
Qian, Y	1
Ances, BM	1
Pruitt, A	1
Choi, B	1
Moonis, G	1
Schuele, SU	1
Kellinghaus, C	1
Shook, SJ	1
Boulis, N	1
Bethoux, FA	1
Loddenkemper, T	1
Boviatsis, EJ	1
Kouyialis, AT	1
Korfias, S	1
Sakas, DE	1
Ben Smail, D	1
Peskine, A	1
Mailhan, L	1
Thiébaut, I	1
Bussel, B	4
Perić, P	1
Antić, B	1
Dincić, E	1
Obradović, D	1
Arsić, S	1
Choudhuri, I	1
Sarvananthan, N	1
Gottlob, I	1
Vender, JR	1
Hughes, BD	1
Hester, S	1
Holsenback, S	1
Rosson, B	1
Quera Salva, MA	1
Benyahia, S	1
Bohic, M	1
Denys, P	3
Al Khudhairi, D	1
Rababa, A	1
Saddiqui, MN	1
Mills, RJ	1
Yap, L	1
Young, CA	1
Sadiq, SA	1
Poopatana, CA	1
Müller, H	2
Fukuhara, T	1
Tanaka, T	1
Namba, Y	1
Kuyama, H	1
McLeod, JG	1
Kiesswetter, H	1
Flamm, J	1
Hennrich, F	1
Summer, K	1
Schober, W	1
Dimitrijevic, MR	1
Sherwood, AM	1
Smolenski, C	1
Muff, S	1
Smolenski-Kautz, S	1
Hering, R	1
Kuritzki, A	1
Bechar, M	1
Larmande, P	1
Larmande, A	1
Hassan, N	1
McLellan, DL	1
Martí-Vilalta, JL	1
Costa-Jussá, F	1
Roig, C	1
Mitchell, G	1
Kroin, JS	2
Ali, A	1
York, M	1
Penn, RD	5
Zak, R	1
Solomon, G	1
Petito, F	1
Labar, D	1
Helén, P	1
Kuurne, T	1
Patterson, V	1
Watt, M	1
Byrnes, D	1
Crowe, D	1
Lee, A	1
Abel, NA	1
Smith, RA	1
Coffey, JR	1
Cahill, D	1
Steers, W	1
Park, TS	1
Ordia, J	1
Meythaler, J	1
Herman, R	1
Levy, R	1
Gill, B	1
Becker, WJ	1
Harris, CJ	1
Long, ML	1
Ablett, DP	1
Klein, GM	1
DeForge, DA	1
Azouvi, P	2
Mane, M	2
Remy-Neris, O	1
Dressnandt, J	3
Conrad, B	3
Ordia, JI	1
Fischer, E	1
Adamski, E	1
Spatz, EL	1
Weinzierl, FX	1
Tölle, TR	1
Konstanzer, A	1
Chartier-Kastler, E	1
Gianino, JM	1
York, MM	1
Paice, JA	1
Shott, S	1
Berg-Johnsen, J	1
Røste, GK	1
Solgaard, T	1
Lundar, T	1
Brenner, R	1
Hyman, N	1
Knobler, R	1
O'Brien, M	1
Stephan, T	1
Fakhoury, T	1
Abou-Khalil, B	1
Blumenkopf, B	1
Rushman, S	1
McLaren, I	1
Auer, C	1
Siebner, HR	1
Kamensek, J	1
Orsnes, GB	1
Sørensen, PS	1
Larsen, TK	1
Ravnborg, M	1
Anderson, JB	1
Orsnes, G	1
Crone, C	1
Krarup, C	1
Petersen, N	1
Nielsen, J	1
Ivanhoe, CB	1
Tilton, AH	1
Francisco, GE	1
Schapiro, RT	1
Hansen, HJ	1
Sunde, N	1
Christensen, JJ	1
Sachais, BA	1
Logue, JN	1
Carey, MS	1
Cendrowski, W	1
Sobczyk, W	1
Feldman, RG	2
Kelly-Hayes, M	1
Conomy, JP	1
Foley, JM	1
Jaffe, R	1
Sawa, GM	1
Paty, DW	1
Reisner, H	1
Duncan, GW	1
Shahani, BT	1
Young, RR	2
Lević, Z	1
Nikolić, M	1
Basmajian, JV	2
Hedley, DW	1
Maroun, JA	1
Espir, ML	1
Landau, WM	1
Aisen, ML	1
Dietz, MA	1
Rossi, P	1
Cedarbaum, JM	1
Kutt, H	1
Saltuari, L	1
Kronenberg, M	1
Marosi, MJ	1
Russegger, L	1
Rifici, C	1
Gerstenbrand, F	1
Smith, MB	2
Brar, SP	2
Nelson, LM	2
Franklin, GM	2
Cobble, ND	2
Smith, CR	1
LaRocca, NG	1
Giesser, BS	1
Scheinberg, LC	1
Lazorthes, Y	1
Sallerin-Caute, B	1
Verdie, JC	1
Bastide, R	1
Carillo, JP	1
Ochs, G	1
Struppler, A	1
Meyerson, BA	1
Linderoth, B	1
Gybels, J	1
Gardner, BP	1
Teddy, P	1
Jamous, A	1
Weinmann, P	1
Pellkofer, M	1
Paulig, M	1
Savoy, SM	2
Corcos, D	2
Latash, M	1
Gottlieb, G	1
Parke, B	2
Rice, GP	2
Rudick, RA	1
Schiffer, RB	1
Herndon, RM	1
Latash, ML	1
Corcos, DM	1
Gottlieb, GL	1
Giesser, B	1
Harrer, G	1
Eyssette, M	1
Rohmer, F	1
Serratrice, G	1
Warter, JM	1
Boisson, D	1
Bass, B	1
Weinshenker, B	1
Noseworthy, JH	1
Cameron, MG	1
Hader, W	1
Bouchard, S	1
Ebers, GC	1
Rogers, JD	1
Stoudemire, GA	1
Hoogstraten, MC	1
van der Ploeg, RJ	1
vd Burg, W	1
Vreeling, A	1
van Marle, S	1
Minderhoud, JM	1
Stien, R	1
Nordal, HJ	1
Oftedal, SI	1
Slettebø, M	1
Zierski, J	1
Dralle, D	1
Börner, U	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Effects of EXOPULSE Mollii Suit on Spasticity and Muscular Oxygenation in Patients With Multiple Sclerosis.[NCT05912595]		36 participants (Anticipated)	Interventional	2023-05-18	Recruiting
Evaluating the Efficacy of Obturator Cryoneurotomy for Hip Adductor Spasticity[NCT05147441]		20 participants (Anticipated)	Observational	2021-08-10	Recruiting
NARCOMS Global Multiple Sclerosis Registry: A Long-Term Study to Facilitate Research in Multiple Sclerosis[NCT01018537]		50,000 participants (Anticipated)	Observational [Patient Registry]	1996-01-31	Recruiting
Using Patient-Reported Outcomes To Improve the Care of People With Multiple Sclerosis: A Randomized Trial[NCT04979546]		356 participants (Anticipated)	Interventional	2021-11-04	Recruiting
Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy: a Prospective, Randomized Study.[NCT00954187]		8 participants (Actual)	Interventional	2009-11-30	Terminated (stopped due to PI left institution)
Exploration of Brain Changes Due to a Targeted Ballet Program in Multiple Sclerosis[NCT04073940]		30 participants (Anticipated)	Interventional	2019-08-29	Recruiting
Intrathecal (IT) Baclofen Drug Distribution Pilot Study[NCT02903823]	Phase 4	27 participants (Actual)	Interventional	2016-04-22	Completed
The Use of Penile Vibratory Stimulation to Decrease Spasticity Following Spinal Cord Injury[NCT00223873]		30 participants	Interventional	2002-11-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"The Modified Ashworth Scale (MAS) is a 6-point scale (Standard MAS scale values: 0, 1, 1.5, 2, 3, or 4) used to evaluate spasticity based on grading muscle tone by moving joints. The MAS scores in this cohort are measured in biceps, triceps and forearm flexor muscles in upper extremities; and quadriceps, hamstrings and gastrocnemius muscles in lower extremities. The score ranges from 0 (no increase in muscle tone) to 4 (affected part(s) rigid in flexion or extension). Improvement in spasticity was a reduction in MAS score by 1 point across a joint tested. Maximal MAS change is the sum of MAS score reduction in all four limbs tested.~This outcome looks at subjects with spasticity of cerebral origin." (NCT02903823)
Timeframe: Baseline to 6 hours post-injection

Subjects Experiencing Maximal MAS Change From Baseline - Spasticity of Spinal Origin

Intervention	Participants (Count of Participants)
	Cervical level 4 injection site	Thoracic level 3 injection site	Thoracic level 10 injection site	Lumbar lever 2 injection site
Subjects With Max MAS Change	8	7	3	3

"The Modified Ashworth Scale (MAS) is a 6-point scale (Standard MAS scale values: 0, 1, 1.5, 2, 3, or 4) used to evaluate spasticity based on grading muscle tone by moving joints. The MAS scores in this cohort are measured in biceps, triceps and forearm flexor muscles in upper extremities; and quadriceps, hamstrings and gastrocnemius muscles in lower extremities. The score ranges from 0 (no increase in muscle tone) to 4 (affected part(s) rigid in flexion or extension). Improvement in spasticity was a reduction in MAS score by 1 point across a joint tested. Maximal MAS change is the sum of MAS score reduction in all four limbs tested.~This outcome looks at subjects with spasticity of spinal origin." (NCT02903823)
Timeframe: Baseline to 6 hours post-injection

Article	Year
A Critical Review of the Role of the Cannabinoid Compounds Δ Molecules (Basel, Switzerland), 2020, Oct-25, Volume: 25, Issue:21 Topics: Analgesics; Animals; Anti-Inflammatory Agents; Baclofen; Cannabidiol; Clinical Trials as Topic; Clon	2020
The effect of symptom-controlling medication on gait outcomes in people with multiple sclerosis: a systematic review. Disability and rehabilitation, 2018, Volume: 40, Issue:15 Topics: 4-Aminopyridine; Baclofen; Cannabinoids; Gait Disorders, Neurologic; Humans; Multiple Sclerosis; Mus	2018
A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiple sclerosis: a systematic review and network meta-analysis. Clinical rehabilitation, 2018, Volume: 32, Issue:6 Topics: Baclofen; Botulinum Toxins, Type A; Cannabinoids; Clonidine; Diazepam; Humans; Multiple Sclerosis; M	2018
A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis. Expert review of neurotherapeutics, 2018, Volume: 18, Issue:10 Topics: Baclofen; Cannabidiol; Disease Progression; Dronabinol; Drug Combinations; Gait Disorders, Neurologi	2018
Intrathecal baclofen in multiple sclerosis. European neurology, 2014, Volume: 72 Suppl 1 Topics: Baclofen; Humans; Injections, Spinal; Multiple Sclerosis; Muscle Relaxants, Central; Muscle Spastici	2014
Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. Multiple sclerosis (Houndmills, Basingstoke, England), 2016, Volume: 22, Issue:11 Topics: Amines; Analgesics; Baclofen; Cannabidiol; Clonidine; Cyclohexanecarboxylic Acids; Dantrolene; Diaze	2016
Intrathecal baclofen in multiple sclerosis: too little, too late? Multiple sclerosis (Houndmills, Basingstoke, England), 2011, Volume: 17, Issue:5 Topics: Baclofen; Cost-Benefit Analysis; Drug Costs; Humans; Infusion Pumps, Implantable; Infusions, Parente	2011
[Pharmacological treatment of spasticity in multiple sclerosis]. Revue neurologique, 2012, Volume: 168 Suppl 3 Topics: Algorithms; Amines; Baclofen; Botulinum Toxins, Type A; Clonidine; Cyclohexanecarboxylic Acids; Dant	2012
Pain and multiple sclerosis: pathophysiology and treatment. Current neurology and neuroscience reports, 2013, Volume: 13, Issue:1 Topics: Analgesics, Opioid; Anticonvulsants; Antidepressive Agents; Baclofen; Cannabinoids; Fatigue; Humans;	2013
A benefit-risk assessment of baclofen in severe spinal spasticity. Drug safety, 2004, Volume: 27, Issue:11 Topics: Administration, Oral; Baclofen; Clinical Trials as Topic; Humans; Injections, Spinal; Multiple Scler	2004
Treatment for ataxia in multiple sclerosis. The Cochrane database of systematic reviews, 2007, Jan-24, Issue:1 Topics: Ataxia; Baclofen; Cannabis; Humans; Multiple Sclerosis; Muscle Relaxants, Central; Phytotherapy; Ran	2007
Management of spasticity in multiple sclerosis by intrathecal baclofen. Acta neurochirurgica. Supplement, 2007, Volume: 97, Issue:Pt 1 Topics: Baclofen; Humans; Injections, Spinal; Multiple Sclerosis; Muscle Relaxants, Central; Muscle Spastici	2007
Functional effects of spinal baclofen. Przeglad lekarski, 2007, Volume: 64 Suppl 2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Baclofen; Child; Child, Preschool; Female; GABA Agonists	2007
Spasticity: medical and surgical treatment. Neurology, 1980, Volume: 30, Issue:7 Pt 2 Topics: Ambulatory Care; Ataxia; Baclofen; Dantrolene; Diazepam; Electric Stimulation; Electrodes; Electroen	1980
Update on multiple sclerosis therapy. The Medical clinics of North America, 1993, Volume: 77, Issue:1 Topics: Amantadine; Baclofen; Fatigue; Humans; Immunosuppression Therapy; Interferons; Multiple Sclerosis; M	1993
[Treatment of spasticity by intrathecal baclofen treatment]. Duodecim; laaketieteellinen aikakauskirja, 1993, Volume: 109, Issue:14 Topics: Baclofen; Female; Humans; Infusion Pumps; Injections, Spinal; Male; Multiple Sclerosis; Muscle Spast	1993
An approach to switching patients from baclofen to tizanidine. Hospital medicine (London, England : 1998), 1998, Volume: 59, Issue:10 Topics: Baclofen; Clinical Competence; Clonidine; Humans; Multiple Sclerosis; Muscle Relaxants, Central; Mus	1998
EEG changes in intrathecal baclofen overdose: a case report and review of the literature. Electroencephalography and clinical neurophysiology, 1998, Volume: 107, Issue:5 Topics: Aged; Baclofen; Electroencephalography; Humans; Injections, Spinal; Male; Multiple Sclerosis; Muscle	1998
Continuous intrathecal baclofen infusions. An introduction and overview. Axone (Dartmouth, N.S.), 1999, Volume: 20, Issue:3 Topics: Adult; Baclofen; Drug Monitoring; Humans; Infusions, Parenteral; Injections, Spinal; Multiple Sclero	1999
Intrathecal baclofen therapy for spastic hypertonia. Physical medicine and rehabilitation clinics of North America, 2001, Volume: 12, Issue:4 Topics: Baclofen; Cerebral Palsy; Drug Overdose; GABA Agonists; Humans; Injections, Spinal; Multiple Scleros	2001
Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis. Current neurology and neuroscience reports, 2001, Volume: 1, Issue:3 Topics: Acetates; Amines; Autoimmune Diseases; Baclofen; Benzodiazepines; Botulinum Toxins, Type A; Cannabin	2001
Drug treatment of multiple sclerosis. Seminars in neurology, 1987, Volume: 7, Issue:2 Topics: Adrenocorticotropic Hormone; Baclofen; Benzodiazepines; Cerebellar Ataxia; Female; Humans; Multiple	1987
Multiple sclerosis. Current concepts in management. Drugs, 1985, Volume: 29, Issue:1 Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Baclofen; Dantrolene; Fatigue; Gastrointestina	1985

Article	Year
Comparison of the effect of baclofen and transcutaneous electrical nerve stimulation for the treatment of spasticity in multiple sclerosis. Neurological research, 2013, Volume: 35, Issue:6 Topics: Adult; Baclofen; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Muscle Relaxants, Central; M	2013
Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity. European neurology, 2016, Volume: 75, Issue:5-6 Topics: Adult; Baclofen; Cannabidiol; Clonidine; Dronabinol; Drug Combinations; Female; Humans; Male; Middle	2016
Pilot study assessing the impact of intrathecal baclofen administration mode on sleep-related respiratory parameters. Archives of physical medicine and rehabilitation, 2012, Volume: 93, Issue:1 Topics: Baclofen; Disabled Persons; Dose-Response Relationship, Drug; Drug Administration Schedule; Female;	2012
Differential effect of baclofen on cortical and spinal inhibitory circuits. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, 2013, Volume: 124, Issue:2 Topics: Adult; Baclofen; Cerebral Cortex; Female; GABA-B Receptor Agonists; H-Reflex; Humans; Injections, Sp	2013
Guided intrathecal baclofen administration by using soleus stretch reflex in moderate-severe spastic multiple sclerosis patients with implanted pump. Multiple sclerosis (Houndmills, Basingstoke, England), 2004, Volume: 10, Issue:5 Topics: Adult; Aged; Baclofen; Female; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; Middle	2004
Long term effect (more than five years) of intrathecal baclofen on impairment, disability, and quality of life in patients with severe spasticity of spinal origin. Journal of neurology, neurosurgery, and psychiatry, 2004, Volume: 75, Issue:11 Topics: Activities of Daily Living; Adult; Aged; Baclofen; Disability Evaluation; Dose-Response Relationship	2004
Intrathecal baclofen and morphine in multiple sclerosis patients with severe pain and spasticity. Journal of neurology, 2007, Volume: 254, Issue:10 Topics: Adult; Baclofen; Drug Therapy, Combination; Female; Humans; Injections, Spinal; Male; Middle Aged; M	2007
A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. Current medical research and opinion, 1981, Volume: 7, Issue:6 Topics: Adult; Aged; Baclofen; Chronic Disease; Clinical Trials as Topic; Clonidine; Double-Blind Method; Fe	1981
Intrathecal baclofen for treatment of intractable spinal spasticity. Archives of physical medicine and rehabilitation, 1994, Volume: 75, Issue:1 Topics: Adult; Baclofen; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hum	1994
Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. Journal of neurosurgery, 1993, Volume: 78, Issue:2 Topics: Adult; Aged; Baclofen; Double-Blind Method; Drug Tolerance; Female; Follow-Up Studies; Humans; Infus	1993
Long-term intrathecal baclofen therapy in patients with intractable spasticity. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1995, Volume: 22, Issue:3 Topics: Adult; Baclofen; Female; Follow-Up Studies; Humans; Injections, Spinal; Male; Middle Aged; Multiple	1995
Intrathecal baclofen administration for control of severe spinal spasticity: functional improvement and long-term follow-up. Archives of physical medicine and rehabilitation, 1996, Volume: 77, Issue:1 Topics: Activities of Daily Living; Adult; Baclofen; Drug Overdose; Female; Follow-Up Studies; Humans; Infus	1996
Chronic intrathecal delivery of baclofen by a programmable pump for the treatment of severe spasticity. Journal of neurosurgery, 1996, Volume: 85, Issue:3 Topics: Adolescent; Adult; Aged; Baclofen; Female; Humans; Injections, Spinal; Male; Middle Aged; Multiple S	1996
Side effects of chronic intrathecal baclofen on erection and ejaculation in patients with spinal cord lesions. Archives of physical medicine and rehabilitation, 1998, Volume: 79, Issue:5 Topics: Adult; Baclofen; Coitus; Ejaculation; Follow-Up Studies; Humans; Infusion Pumps, Implantable; Inject	1998
Peripheral and central effect of baclofen on ankle joint stiffness in multiple sclerosis. Muscle & nerve, 2000, Volume: 23, Issue:1 Topics: Adult; Ankle Joint; Baclofen; Biomechanical Phenomena; Central Nervous System; Electromyography; Ele	2000
Effect of baclofen on gait in spastic MS patients. Acta neurologica Scandinavica, 2000, Volume: 101, Issue:4 Topics: Adult; Analysis of Variance; Baclofen; Cross-Over Studies; Dose-Response Relationship, Drug; Double-	2000
Baclofen increases the soleus stretch reflex threshold in the early swing phase during walking in spastic multiple sclerosis patients. Multiple sclerosis (Houndmills, Basingstoke, England), 2000, Volume: 6, Issue:2 Topics: Adult; Baclofen; Differential Threshold; Electromyography; Female; Gait; Humans; Male; Middle Aged;	2000
Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis. Archives of neurology, 1977, Volume: 34, Issue:7 Topics: Adolescent; Adult; Aminobutyrates; Baclofen; Chemical Phenomena; Chemistry; Clinical Trials as Topic	1977
Clonazepam, baclofen and placebo in the treatment of spasticity. European neurology, 1977, Volume: 16, Issue:1-6 Topics: Adolescent; Adult; Aged; Aminobutyrates; Baclofen; Benzodiazepinones; Clinical Trials as Topic; Clon	1977
Baclofen for spasticity in multiple sclerosis. Double-blind crossover and three-year study. Neurology, 1978, Volume: 28, Issue:11 Topics: Activities of Daily Living; Adult; Aminobutyrates; Baclofen; Clinical Trials as Topic; Double-Blind	1978
Clinical effects of multiple sclerosis therapy. Neurology, 1979, Volume: 29, Issue:5 Topics: Aminobutyrates; Baclofen; Clinical Trials as Topic; Double-Blind Method; Humans; Multiple Sclerosis	1979
The use of baclofen in treatment of spasticity in multiple sclerosis. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1979, Volume: 6, Issue:3 Topics: Adult; Baclofen; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged; M	1979
An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions. A double-blind, cross-over study. Neurology, 1976, Volume: 26, Issue:5 Topics: Adult; Aminobutyrates; Baclofen; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Male; Mo	1976
Lioresal (baclofen) treatment of spasticity in multiple sclerosis. American journal of physical medicine, 1975, Volume: 54, Issue:4 Topics: Adult; Aminobutyrates; Baclofen; Clinical Trials as Topic; Humans; Middle Aged; Multiple Sclerosis;	1975
Evaluation of baclofen (Lioresal) for spasticity in multiple sclerosis. Postgraduate medical journal, 1975, Volume: 51, Issue:599 Topics: Adult; Aged; Aminobutyrates; Baclofen; Clinical Trials as Topic; Female; Humans; Male; Middle Aged;	1975
Indication, efficiency and complications of intrathecal pump supported baclofen treatment in spinal spasticity. Acta neurologica, 1992, Volume: 14, Issue:3 Topics: Adult; Baclofen; Female; Follow-Up Studies; Hemangioma; Humans; Infusion Pumps; Injections, Spinal;	1992
Baclofen effect on quadriceps strength in multiple sclerosis. Archives of physical medicine and rehabilitation, 1992, Volume: 73, Issue:3 Topics: Activities of Daily Living; Adult; Baclofen; Female; Humans; Middle Aged; Multiple Sclerosis; Muscle	1992
Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis. Archives of physical medicine and rehabilitation, 1991, Volume: 72, Issue:3 Topics: Adult; Baclofen; Clinical Protocols; Combined Modality Therapy; Double-Blind Method; Evaluation Stud	1991
Intrathecal baclofen for long-term treatment of spasticity: a multi-centre study. Journal of neurology, neurosurgery, and psychiatry, 1989, Volume: 52, Issue:8 Topics: Adult; Baclofen; Catheters, Indwelling; Clinical Trials as Topic; Electromyography; Female; Follow-U	1989
[Comparative double-blind study of the effectiveness and tolerance of baclofen, tetrazepam and tizanidine in spastic movement disorders of the lower extremities]. Medizinische Klinik (Munich, Germany : 1983), 1989, Jan-15, Volume: 84, Issue:1 Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Baclofen; Benzodiazepines; Benzodiazepinones; Clinical	1989
Intrathecal baclofen for severe spinal spasticity. The New England journal of medicine, 1989, Jun-08, Volume: 320, Issue:23 Topics: Adult; Baclofen; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Infusion Pumps; Male	1989
Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. Current medical research and opinion, 1988, Volume: 10, Issue:10 Topics: Adult; Aged; Baclofen; Clinical Trials as Topic; Clonidine; Double-Blind Method; Female; Humans; Mal	1988
Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1988, Volume: 15, Issue:1 Topics: Adult; Aged; Baclofen; Brain; Clonidine; Dose-Response Relationship, Drug; Female; Humans; Male; Mid	1988
The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen. Acta neurologica Scandinavica, 1987, Volume: 75, Issue:3 Topics: Adult; Aged; Baclofen; Clinical Trials as Topic; Clonidine; Double-Blind Method; Drug Tolerance; Fem	1987

Article	Year
GABA Glia, 2022, Volume: 70, Issue:12 Topics: Animals; Baclofen; Cell Differentiation; Central Nervous System; GABA-B Receptor Agonists; Lysophosp	2022
Reasons and Determinants of BoNT-A Treatment Discontinuation in Patients Living with Spasticity: A 10-Year Retrospective Analysis. Toxins, 2022, 09-29, Volume: 14, Issue:10 Topics: Baclofen; Botulinum Toxins, Type A; Brain Injuries, Traumatic; Humans; Middle Aged; Multiple Scleros	2022
Spasticity treatment patterns among people with multiple sclerosis: a Swedish cohort study. Journal of neurology, neurosurgery, and psychiatry, 2023, Volume: 94, Issue:5 Topics: Baclofen; Cohort Studies; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscl	2023
Effects of intrathecal Baclofen in reducing tremors in patients with multiple sclerosis. Neurosciences (Riyadh, Saudi Arabia), 2023, Volume: 28, Issue:2 Topics: Adult; Baclofen; Humans; Injections, Spinal; Male; Multiple Sclerosis; Muscle Relaxants, Central; Mu	2023
Italian consensus on treatment of spasticity in multiple sclerosis. European journal of neurology, 2020, Volume: 27, Issue:3 Topics: Baclofen; Botulinum Toxins; Clonidine; Consensus; Disease Management; Gabapentin; Humans; Injections	2020
Intrathecal baclofen pump exchange in multiple sclerosis. Factors affecting baclofen efficacy and dose adjustement. A case report. Revista espanola de anestesiologia y reanimacion, 2021, Volume: 68, Issue:3 Topics: Baclofen; Humans; Multiple Sclerosis; Muscle Relaxants, Central; Muscle Spasticity; Quality of Life	2021
Evaluation of the impact of intrathecal baclofen on the walking ability of people with Multiple Sclerosis related spasticity. Multiple sclerosis and related disorders, 2020, Volume: 46 Topics: Baclofen; Female; Humans; Injections, Spinal; Male; Middle Aged; Multiple Sclerosis; Muscle Relaxant	2020
Evaluation of the cognitive benefits of intrathecal baclofen pump implantation in people with intractable multiple sclerosis related spasticity. Multiple sclerosis and related disorders, 2021, Volume: 50 Topics: Baclofen; Cognition; Humans; Injections, Spinal; Middle Aged; Multiple Sclerosis; Muscle Relaxants,	2021
Early outcomes after intrathecal baclofen therapy in ambulatory patients with multiple sclerosis. Journal of neurosurgery, 2018, Volume: 129, Issue:4 Topics: Administration, Oral; Aged; Ambulatory Care; Baclofen; Clonidine; Drug Therapy, Combination; Female;	2018
Colonic perforation by an intrathecal baclofen pump catheter causing delayed BMJ case reports, 2017, Dec-20, Volume: 2017 Topics: Anti-Bacterial Agents; Baclofen; Catheterization; Catheters, Indwelling; Device Removal; Disabled Pe	2017
Spasticity Treatment Ameliorates the Efficacy of Melatonin Therapy in Experimental Autoimmune Encephalomyelitis (EAE) Mouse Model of Multiple Sclerosis. Cellular and molecular neurobiology, 2018, Volume: 38, Issue:5 Topics: Animals; Baclofen; Biomarkers; Cytokines; Disease Models, Animal; Encephalomyelitis, Autoimmune, Exp	2018
Intrathecal baclofen for multiple sclerosis related spasticity: A twenty year experience. Multiple sclerosis and related disorders, 2019, Volume: 27 Topics: Adult; Aged; Baclofen; Female; Humans; Injections, Spinal; Male; Middle Aged; Multiple Sclerosis; Mu	2019
Intrathecal Baclofen Therapy in Patients With Multiple Sclerosis: Improved Outcomes and Reduced Costs Through Identification of Catheter Malfunction. Neuromodulation : journal of the International Neuromodulation Society, 2019, Volume: 22, Issue:7 Topics: Adult; Aged; Baclofen; Catheters, Indwelling; Female; Health Care Costs; Humans; Infusion Pumps, Imp	2019
Cortical reorganization in multiple sclerosis after intrathecal baclofen therapy. Neurocase, 2014, Volume: 20, Issue:2 Topics: Baclofen; Brain; Brain Mapping; Female; GABA-B Receptor Agonists; Humans; Injections, Spinal; Magnet	2014
Costs and quality of life in multiple sclerosis patients with spasticity. Acta neurologica Scandinavica, 2014, Volume: 129, Issue:1 Topics: Absenteeism; Adult; Aged; Aged, 80 and over; Baclofen; Botulinum Toxins; Caregivers; Cost of Illness	2014
Intrathecal baclofen in multiple sclerosis and spinal cord injury: complications and long-term dosage evolution. Clinical rehabilitation, 2013, Volume: 27, Issue:12 Topics: Baclofen; Belgium; Dose-Response Relationship, Drug; Female; Humans; Infusion Pumps, Implantable; In	2013
Special considerations when coding for patients with multiple sclerosis. Continuum (Minneapolis, Minn.), 2013, Volume: 19, Issue:4 Multiple Topics: Baclofen; Clinical Coding; Humans; Infusion Pumps, Implantable; Multiple Sclerosis; Muscle Relaxants	2013
[Radiotherapy and implantable medical device: example of infusion pumps]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2013, Volume: 17, Issue:8 Topics: Baclofen; Carcinoma, Squamous Cell; Dose Fractionation, Radiation; Female; Humans; Infusion Pumps, I	2013
Occurrence of adverse events in long-term intrathecal baclofen infusion: a 1-year follow-up study of 158 adults. Archives of physical medicine and rehabilitation, 2014, Volume: 95, Issue:6 Topics: Adolescent; Adult; Age Distribution; Aged; Baclofen; Cerebral Palsy; Dose-Response Relationship, Dru	2014
Patient experiences with intrathecal baclofen as a treatment for spasticity - a pilot study. Disability and rehabilitation, 2015, Volume: 37, Issue:10 Topics: Activities of Daily Living; Adult; Aged; Baclofen; Cerebral Palsy; Female; Humans; Injections, Spina	2015
Spasticity. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2015, Apr-07, Volume: 187, Issue:6 Topics: Baclofen; Botulinum Toxins; Cerebral Palsy; Humans; Multiple Sclerosis; Muscle Relaxants, Central; M	2015
Intrathecal Baclofen Dosing Regimens: A Retrospective Chart Review. Neuromodulation : journal of the International Neuromodulation Society, 2016, Volume: 19, Issue:6 Topics: Adult; Aged; Baclofen; Brain Injuries; Cerebral Palsy; Dose-Response Relationship, Drug; Female; Hum	2016
THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms. European neurology, 2016, Volume: 75 Suppl 1 Topics: Adult; Amines; Baclofen; Calcium Channel Blockers; Cannabidiol; Cohort Studies; Cyclohexanecarboxyli	2016
Long-term effects of intrathecal baclofen in multiple sclerosis. Clinical neurology and neurosurgery, 2016, Volume: 143 Topics: Adult; Baclofen; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Infusion Pumps	2016
Effects of severe spasticity treatment with intrathecal Baclofen in multiple sclerosis patients: Long term follow-up. NeuroRehabilitation, 2016, Apr-06, Volume: 38, Issue:4 Topics: Adult; Baclofen; Female; Follow-Up Studies; Humans; Infusion Pumps, Implantable; Injections, Spinal;	2016
Palliative Care in Multiple Sclerosis. Continuum (Minneapolis, Minn.), 2016, Volume: 22, Issue:3 Topics: Adult; Antidepressive Agents; Baclofen; Caregivers; Female; Humans; Injections, Spinal; Multiple Scl	2016
Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice. European neurology, 2016, Volume: 76, Issue:5-6 Topics: Activities of Daily Living; Adult; Baclofen; Cannabidiol; Dronabinol; Drug Combinations; Female; Hum	2016
The safety of baclofen in pregnancy: intrathecal therapy in multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England), 2008, Volume: 14, Issue:4 Topics: Adult; Baclofen; Female; GABA Agonists; Humans; Infant, Newborn; Injections, Spinal; Male; Multiple	2008
The incidence and management of tolerance in intrathecal baclofen therapy. Spinal cord, 2009, Volume: 47, Issue:10 Topics: Adolescent; Adult; Aged; Baclofen; Cohort Studies; Dose-Response Relationship, Drug; Drug Tolerance;	2009
Drug rash with eosinophilia and systemic signs syndrome in a patient with multiple sclerosis. Clinical therapeutics, 2009, Volume: 31, Issue:3 Topics: Administration, Oral; Adult; Baclofen; Biopsy; Chemical and Drug Induced Liver Injury; Cholestasis;	2009
Tolerance to continuous intrathecal baclofen infusion can be reversed by pulsatile bolus infusion. Spinal cord, 2010, Volume: 48, Issue:6 Topics: Baclofen; Drug Tolerance; Female; Follow-Up Studies; Humans; Infusion Pumps, Implantable; Injections	2010
Cranial migration of a baclofen pump catheter associated with subarachnoid hemorrhage: case report. Neurosurgery, 2009, Volume: 65, Issue:6 Topics: Baclofen; Foreign-Body Migration; Humans; Magnetic Resonance Angiography; Magnetic Resonance Imaging	2009
Clinical outcome and complications of intrathecal baclofen pump in multiple sclerosis patients: a retrospective study. NeuroRehabilitation, 2010, Volume: 27, Issue:2 Topics: Adult; Baclofen; Equipment Failure; Female; Foreign-Body Migration; Humans; Infusion Pumps, Implanta	2010
Treatment of spasticity related to multiple sclerosis with intrathecal baclofen: a long-term follow-up. Journal of rehabilitation medicine, 2011, Volume: 43, Issue:6 Topics: Adult; Baclofen; Disability Evaluation; Drug Implants; Female; Follow-Up Studies; Humans; Injections	2011
Pharmacological tests of hypotheses for acquired pendular nystagmus. Annals of the New York Academy of Sciences, 2011, Volume: 1233 Topics: Amines; Baclofen; Cerebellar Cortex; Cyclohexanecarboxylic Acids; Eye Movements; Gabapentin; gamma-A	2011
Paraspinal subfascial placement of lumbar intrathecal baclofen catheters: short-term outcomes of a novel technique. Journal of neurosurgery. Pediatrics, 2012, Volume: 9, Issue:1 Topics: Adolescent; Adult; Baclofen; Catheters, Indwelling; Cerebral Palsy; Child; Child, Preschool; Dystoni	2012
Accidental intoxication with 60 mg intrathecal baclofen: survived. Neurocritical care, 2012, Volume: 16, Issue:3 Topics: Baclofen; Critical Care; Female; Humans; Infusion Pumps, Implantable; Injections, Spinal; Middle Age	2012
Twisted catheter causing baclofen pump malfunction: a case report. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2012, Volume: 39, Issue:6 Topics: Baclofen; Catheters; Humans; Infusion Pumps, Implantable; Male; Middle Aged; Multiple Sclerosis; Mus	2012
Improvement of acquired pendular nystagmus by gabapentin: case report. Bulletin de la Societe belge d'ophtalmologie, 2001, Issue:282 Topics: Acetates; Administration, Oral; Amines; Baclofen; Cyclohexanecarboxylic Acids; Female; Gabapentin; g	2001
Spasticity in multiple sclerosis. Neurorehabilitation and neural repair, 2003, Volume: 17, Issue:1 Topics: Adult; Aged; Anti-Dyskinesia Agents; Baclofen; Botulinum Toxins; Disability Evaluation; Female; Huma	2003
Attenuation of cerebellar tremor with implantation of an intrathecal baclofen pump: the role of gamma-aminobutyric acidergic pathways. Case report. Journal of neurosurgery, 2003, Volume: 99, Issue:4 Topics: Baclofen; Cerebellum; Female; GABA Agonists; gamma-Aminobutyric Acid; Humans; Infusion Pumps, Implan	2003
Prevalence and treatment of spasticity reported by multiple sclerosis patients. Multiple sclerosis (Houndmills, Basingstoke, England), 2004, Volume: 10, Issue:5 Topics: Administration, Oral; Adult; Baclofen; Cross-Sectional Studies; Disability Evaluation; Female; Human	2004
Prevalence and treatment of spasticity reported by multiple sclerosis patients. Multiple sclerosis (Houndmills, Basingstoke, England), 2004, Volume: 10, Issue:5 Topics: Administration, Oral; Adult; Baclofen; Cross-Sectional Studies; Disability Evaluation; Female; Human	2004
Prevalence and treatment of spasticity reported by multiple sclerosis patients. Multiple sclerosis (Houndmills, Basingstoke, England), 2004, Volume: 10, Issue:5 Topics: Administration, Oral; Adult; Baclofen; Cross-Sectional Studies; Disability Evaluation; Female; Human	2004
Prevalence and treatment of spasticity reported by multiple sclerosis patients. Multiple sclerosis (Houndmills, Basingstoke, England), 2004, Volume: 10, Issue:5 Topics: Administration, Oral; Adult; Baclofen; Cross-Sectional Studies; Disability Evaluation; Female; Human	2004
Prevalence and treatment of spasticity reported by multiple sclerosis patients. Multiple sclerosis (Houndmills, Basingstoke, England), 2004, Volume: 10, Issue:5 Topics: Administration, Oral; Adult; Baclofen; Cross-Sectional Studies; Disability Evaluation; Female; Human	2004
Prevalence and treatment of spasticity reported by multiple sclerosis patients. Multiple sclerosis (Houndmills, Basingstoke, England), 2004, Volume: 10, Issue:5 Topics: Administration, Oral; Adult; Baclofen; Cross-Sectional Studies; Disability Evaluation; Female; Human	2004
Prevalence and treatment of spasticity reported by multiple sclerosis patients. Multiple sclerosis (Houndmills, Basingstoke, England), 2004, Volume: 10, Issue:5 Topics: Administration, Oral; Adult; Baclofen; Cross-Sectional Studies; Disability Evaluation; Female; Human	2004
Prevalence and treatment of spasticity reported by multiple sclerosis patients. Multiple sclerosis (Houndmills, Basingstoke, England), 2004, Volume: 10, Issue:5 Topics: Administration, Oral; Adult; Baclofen; Cross-Sectional Studies; Disability Evaluation; Female; Human	2004
Prevalence and treatment of spasticity reported by multiple sclerosis patients. Multiple sclerosis (Houndmills, Basingstoke, England), 2004, Volume: 10, Issue:5 Topics: Administration, Oral; Adult; Baclofen; Cross-Sectional Studies; Disability Evaluation; Female; Human	2004
Spastic paretic hemifacial contracture (SPHC) in a patient with multiple sclerosis. A clinical, EMG and neuroimaging study. Neurophysiologie clinique = Clinical neurophysiology, 2004, Volume: 34, Issue:3-4 Topics: Adult; Amines; Baclofen; Blinking; Brain; Clonazepam; Cyclohexanecarboxylic Acids; Electromyography;	2004
Total knee replacement in patients with multiple sclerosis. The Knee, 2004, Volume: 11, Issue:6 Topics: Aged; Arthroplasty, Replacement, Knee; Baclofen; Braces; Casts, Surgical; Humans; Immobilization; Kn	2004
Intrathecal baclofen therapy over 10 years. The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses, 2004, Volume: 36, Issue:6 Topics: Adolescent; Adult; Baclofen; Brain Injuries; Cerebral Palsy; Child; Child, Preschool; Drug Implants;	2004
Intracranial fat embolization due to baclofen pump. Neurology, 2005, Mar-08, Volume: 64, Issue:5 Topics: Adult; Baclofen; Brain; Embolism, Fat; Female; Headache; Humans; Hyperacusis; Infusion Pumps, Implan	2005
Incidence of seizures in patients with multiple sclerosis treated with intrathecal baclofen. Neurology, 2005, Mar-22, Volume: 64, Issue:6 Topics: Adult; Baclofen; Brain; Case-Control Studies; Cohort Studies; Female; GABA Agonists; Humans; Inciden	2005
Functional outcome of intrathecal baclofen administration for severe spasticity. Clinical neurology and neurosurgery, 2005, Volume: 107, Issue:4 Topics: Activities of Daily Living; Adult; Baclofen; Female; Follow-Up Studies; Humans; Infusion Pumps, Impl	2005
Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients. Multiple sclerosis (Houndmills, Basingstoke, England), 2006, Volume: 12, Issue:1 Topics: Adult; Aged; Baclofen; Disabled Persons; Humans; Injections, Spinal; Middle Aged; Multiple Sclerosis	2006
[Treatment of severe spacticity in multiple sclerosis by continuous intrathecal baclofen]. Vojnosanitetski pregled, 2006, Volume: 63, Issue:2 Topics: Adult; Baclofen; Female; Humans; Infusion Pumps, Implantable; Injections, Spinal; Middle Aged; Multi	2006
Survey of management of acquired nystagmus in the United Kingdom. Eye (London, England), 2007, Volume: 21, Issue:9 Topics: Amines; Baclofen; Cyclohexanecarboxylic Acids; Drug Utilization; Excitatory Amino Acid Antagonists;	2007
Intrathecal baclofen therapy and multiple sclerosis: outcomes and patient satisfaction. Neurosurgical focus, 2006, Aug-15, Volume: 21, Issue:2 Topics: Baclofen; Body Weight; Caregivers; Female; Follow-Up Studies; Humans; Infusion Pumps, Implantable; I	2006
Effect of intrathecal baclofen on sleep and respiratory function in patients with spasticity. Neurology, 2006, Oct-24, Volume: 67, Issue:8 Topics: Adult; Baclofen; Circadian Rhythm; Female; Humans; Injections, Spinal; Middle Aged; Multiple Scleros	2006
Intrathecal baclofen for muscle spasticity and pain--two case reports. Middle East journal of anaesthesiology, 2006, Volume: 18, Issue:5 Topics: Adult; Baclofen; Female; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; Middle Aged;	2006
Tangled catheter as a rare cause of baclofen pump malfunction. Surgical neurology, 2009, Volume: 72, Issue:1 Topics: Baclofen; Catheters, Indwelling; Female; Humans; Infusion Pumps, Implantable; Middle Aged; Multiple	2009
When drugs can help in multiple sclerosis. Drugs, 1980, Volume: 19, Issue:6 Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Baclofen; Dantrolene; Diazepam; Humans; Immuno	1980
[Urological complications in patients with multiple sclerosis (author's transl)]. Wiener klinische Wochenschrift, 1980, Jan-04, Volume: 92, Issue:1 Topics: Adolescent; Adult; Aged; Baclofen; Electric Stimulation; Emepronium; Female; Humans; Male; Middle Ag	1980
[Baclofen in trigeminal neuritis]. Harefuah, 1982, Jan-15, Volume: 102, Issue:2 Topics: Baclofen; Female; Humans; Middle Aged; Multiple Sclerosis; Trigeminal Neuralgia	1982
[The action of baclofen on periodic alternating nystagmus. Current perspectives in the treatment of certain forms of nystagmus]. Bulletins et memoires de la Societe francaise d'ophtalmologie, 1982, Volume: 94 Topics: Baclofen; Eye Movements; Humans; Male; Middle Aged; Multiple Sclerosis; Nystagmus, Pathologic	1982
Double-blind comparison of single doses of DS103-282, baclofen and placebo for suppression of spasticity. Journal of neurology, neurosurgery, and psychiatry, 1980, Volume: 43, Issue:12 Topics: Adolescent; Adult; Aged; Baclofen; Clonidine; Double-Blind Method; Electromyography; Female; Hemiple	1980
[Multiple sclerosis. Treatment interactions]. Medicina clinica, 1981, Oct-10, Volume: 77, Issue:6 Topics: Adult; Baclofen; Carbamazepine; Drug Interactions; Humans; Male; Multiple Sclerosis; Muscle Spastici	1981
The distribution of medication along the spinal canal after chronic intrathecal administration. Neurosurgery, 1993, Volume: 33, Issue:2 Topics: Analgesia, Epidural; Baclofen; Endometrial Neoplasms; Female; Humans; Hydromorphone; Infusion Pumps,	1993
Baclofen-induced generalized nonconvulsive status epilepticus. Annals of neurology, 1994, Volume: 36, Issue:1 Topics: Baclofen; Electroencephalography; Female; Humans; Middle Aged; Multiple Sclerosis; Status Epilepticu	1994
Management of severe spasticity with intrathecal baclofen delivered by a manually operated pump. Journal of neurology, neurosurgery, and psychiatry, 1994, Volume: 57, Issue:5 Topics: Adult; Aged; Baclofen; Humans; Infusion Pumps, Implantable; Injections, Spinal; Middle Aged; Multipl	1994
Lasting reduction of severe spasticity after ending chronic treatment with intrathecal baclofen. Journal of neurology, neurosurgery, and psychiatry, 1996, Volume: 60, Issue:2 Topics: Adult; Aged; Baclofen; Female; Humans; Injections, Spinal; Male; Middle Aged; Multiple Sclerosis; Mu	1996
Acute overdose of intrathecal baclofen. Journal of neurology, 1996, Volume: 243, Issue:6 Topics: Adult; Baclofen; Drug Overdose; Female; Humans; Infusion Pumps; Injections, Spinal; Medication Error	1996
Quality of life: effect of reduced spasticity from intrathecal baclofen. The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses, 1998, Volume: 30, Issue:1 Topics: Adult; Aged; Baclofen; Female; Humans; Infusion Pumps, Implantable; Infusions, Parenteral; Male; Mid	1998
[Continuous intrathecal infusion of baclofen. A new therapeutic method for spasticity]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1998, Sep-10, Volume: 118, Issue:21 Topics: Adolescent; Adult; Baclofen; Child; Female; Follow-Up Studies; Humans; Infusion Pumps, Implantable;	1998
Management of intra-thecal baclofen overdose. Intensive care medicine, 1999, Volume: 25, Issue:2 Topics: Antidotes; Baclofen; Drug Overdose; Equipment Failure; Female; GABA Agonists; Humans; Infusion Pumps	1999
Intrathecal baclofen increases corticospinal output to hand muscles in multiple sclerosis. Neurology, 1999, Apr-12, Volume: 52, Issue:6 Topics: Adult; Baclofen; Evoked Potentials, Motor; Female; Hand; Humans; Injections, Spinal; Male; Middle Ag	1999
The effect of baclofen on the transmission in spinal pathways in spastic multiple sclerosis patients. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, 2000, Volume: 111, Issue:8 Topics: Administration, Oral; Adult; Baclofen; Electric Stimulation; Electromyography; Female; H-Reflex; Hum	2000
Evidence of tolerance to baclofen in treatment of severe spasticity with intrathecal baclofen. Clinical neurology and neurosurgery, 2002, Volume: 104, Issue:2 Topics: Adult; Baclofen; Catheterization; Drug Administration Schedule; Female; Humans; Injections, Spinal;	2002
Hallucinations after sudden withdrawal of baclofen. Lancet (London, England), 1977, Jul-02, Volume: 2, Issue:8027 Topics: Aminobutyrates; Baclofen; Female; Hallucinations; Humans; Middle Aged; Multiple Sclerosis; Substance	1977
[Pharmacological treatment of pathological increases in muscle tonus]. Wiener medizinische Wochenschrift (1946), 1978, Feb-15, Volume: 128, Issue:3 Topics: Baclofen; Chlorzoxazone; Female; Humans; Multiple Sclerosis; Muscle Spasticity; Neural Pathways; Par	1978
Baclofen (Lioresal). A new muscle relaxant for multiple sclerosis. The Medical letter on drugs and therapeutics, 1978, May-05, Volume: 20, Issue:9 Topics: Aminobutyrates; Baclofen; Humans; Multiple Sclerosis	1978
Baclofen. Archives of neurology, 1977, Volume: 34, Issue:11 Topics: Aminobutyrates; Baclofen; Drug Evaluation; Humans; Multiple Sclerosis; Muscle Spasticity	1977
[Myotonolytic effect of Lioresal-A]. Srpski arhiv za celokupno lekarstvo, 1976, Volume: 104, Issue:5 Topics: Adult; Aminobutyrates; Baclofen; Drug Evaluation; Female; Humans; Male; Middle Aged; Multiple Sclero	1976
Baclofen for spasticity. Neurology, 1992, Volume: 42, Issue:10 Topics: Baclofen; Dose-Response Relationship, Drug; Humans; Multiple Sclerosis; Muscle Spasticity	1992
Clinical and pharmacokinetic aspects of high dose oral baclofen therapy. The Journal of the American Paraplegia Society, 1992, Volume: 15, Issue:4 Topics: Administration, Oral; Adult; Aged; Baclofen; Dose-Response Relationship, Drug; Female; Humans; Male;	1992
Intrathecal baclofen for spasticity of spinal origin: seven years of experience. Journal of neurosurgery, 1992, Volume: 77, Issue:2 Topics: Adolescent; Adult; Aged; Baclofen; Catheterization; Child; Equipment Failure; Female; Humans; Infusi	1992
High-dose oral baclofen: experience in patients with multiple sclerosis. Neurology, 1991, Volume: 41, Issue:11 Topics: Administration, Oral; Adolescent; Adult; Aged; Baclofen; Female; Humans; Male; Middle Aged; Multiple	1991
Chronic intrathecal baclofen administration for control of severe spasticity. Journal of neurosurgery, 1990, Volume: 72, Issue:3 Topics: Baclofen; Coma; Drug Overdose; Drug Tolerance; Evaluation Studies as Topic; Humans; Infusion Pumps,	1990
Tizanidine vs. baclofen in the treatment of spasticity in patients with multiple sclerosis. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1989, Volume: 16, Issue:4 Topics: Baclofen; Clonidine; Drug Tolerance; Humans; Multiple Sclerosis; Muscle Spasticity	1989
Short-term effects of intrathecal baclofen in spasticity. Experimental neurology, 1989, Volume: 103, Issue:2 Topics: Administration, Oral; Adult; Baclofen; Electromyography; Humans; Injections, Spinal; Knee Joint; Mid	1989
Functional outcome after delivery of intrathecal baclofen. Archives of physical medicine and rehabilitation, 1989, Volume: 70, Issue:1 Topics: Activities of Daily Living; Adult; Baclofen; Female; Humans; Injections, Spinal; Male; Middle Aged;	1989
[Therapy of multiple sclerosis]. Wiener medizinische Wochenschrift (1946), 1985, Jan-31, Volume: 135, Issue:1-2 Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Azathioprine; Baclofen; Combined Modality Ther	1985
Neuroleptic malignant syndrome in multiple sclerosis. Possible masking effects of antispasmodics. Psychosomatics, 1988,Spring, Volume: 29, Issue:2 Topics: Adult; Baclofen; Female; Humans; Multiple Sclerosis; Neuroleptic Malignant Syndrome	1988
Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients. Acta neurologica Scandinavica, 1988, Volume: 77, Issue:3 Topics: Adult; Aged; Baclofen; Clonidine; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Age	1988
The effect of intrathecal baclofen on electrical muscle activity in spasticity. Journal of neurology, 1987, Volume: 234, Issue:5 Topics: Adult; Aged; Baclofen; Brain Damage, Chronic; Child, Preschool; Electromyography; Humans; Infusion P	1987
Intrathecal baclofen for severe spasticity. The Medical journal of Australia, 1987, Sep-07, Volume: 147, Issue:5 Topics: Baclofen; Humans; Infusion Pumps; Multiple Sclerosis; Muscle Spasticity	1987
Muscle relaxants in multiple sclerosis. International disability studies, 1987, Volume: 9, Issue:2 Topics: Baclofen; Dantrolene; Humans; Multiple Sclerosis; Muscle Spasticity	1987
Intrathecal baclofen for severe spasticity. The Medical journal of Australia, 1986, Nov-03, Volume: 145, Issue:9 Topics: Adult; Baclofen; Catheters, Indwelling; Female; Humans; Injections, Spinal; Multiple Sclerosis; Musc	1986
Determination of 4-amino-3-(p-chlorophenyl)butyric acid (baclofen) in plasma by high-performance liquid chromatography. Journal of chromatography, 1985, May-03, Volume: 339, Issue:2 Topics: Baclofen; Chromatography, High Pressure Liquid; Humans; Multiple Sclerosis; Time Factors	1985
Baclofen-induced memory impairment. Clinical neuropharmacology, 1985, Volume: 8, Issue:3 Topics: Adult; Baclofen; Female; Humans; Memory, Short-Term; Middle Aged; Multiple Sclerosis; Spasm; Trigemi	1985

baclofen and MS (Multiple Sclerosis)